Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Angiostatic versus angiogenic chemokines in IPF and EAA

S. Martina, V. Martina, M. Monika, P. Jan, K. Libor, S. Ilja,

. 2009 ; 103 (11) : 1651-1656. [pub] 20090616

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12026042

Grantová podpora
NR9131 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Extrinsic allergic alveolitis (EAA) and idiopathic pulmonary fibrosis (IPF) share the presence of varying degree interstitial involvement and fibrosis. Vascular changes were often reported to accompany the development of fibrosis. OBJECTIVES: The aim of our study was to examine the differences in angiostatic and angiogenic chemokine milieu in both diseases. Correlations between chemokine levels in bronchoalveolar lavage fluid (BALF), expression of chemokine receptors on CD4+ T cells (CXCR2, CXCR3) in BALF and HRCT pattern of the diseases were investigated. METHODS: Sixteen patients with chronic EAA and 8 with IPF were enrolled to the study. Concentrations of interleukin (IL)-8, epithelial neutrophil activating protein (ENA)-78, interferon-gamma-inducible protein (IP)-10 and interferon-inducible T cell alpha chemoattractant (I-TAC) in BALF supernatants were quantified using Fluorokine MultiAnalyte profiling. RESULTS: There was no significant difference in the BALF chemokine levels between the EAA and IPF group. IL-8 BALF concentrations correlate with the extent of fibrosis in both EAA and IPF (p<0.01). The IP-10 BALF concentrations do not correlate either with the HRCT alveolar or interstitial score and should be evaluated in the relationship with the disease course. CONCLUSIONS: Both IL-8 and ENA-78 probably play a different role in IPF and chronic EAA pathogenesis. While we suggest ENA-78 as the marker of at least partial reversibility of the lung impairment in the EAA patients, IL-8 could be rather an indicator of continuous exposition to provoking agent in EAA patients. IL-8 might serve as a potential marker of early phase of IPF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026042
003      
CZ-PrNML
005      
20140318134341.0
007      
ta
008      
120817e20090616enk f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.rmed.2009.05.012 $2 doi
035    __
$a (PubMed)19535235
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Martina, Sterclova $u Department of Respiratory Medicine, Thomayer's University Hospital, Prague, Czech Republic. martinasafrankova@seznam.cz
245    10
$a Angiostatic versus angiogenic chemokines in IPF and EAA / $c S. Martina, V. Martina, M. Monika, P. Jan, K. Libor, S. Ilja,
520    9_
$a BACKGROUND: Extrinsic allergic alveolitis (EAA) and idiopathic pulmonary fibrosis (IPF) share the presence of varying degree interstitial involvement and fibrosis. Vascular changes were often reported to accompany the development of fibrosis. OBJECTIVES: The aim of our study was to examine the differences in angiostatic and angiogenic chemokine milieu in both diseases. Correlations between chemokine levels in bronchoalveolar lavage fluid (BALF), expression of chemokine receptors on CD4+ T cells (CXCR2, CXCR3) in BALF and HRCT pattern of the diseases were investigated. METHODS: Sixteen patients with chronic EAA and 8 with IPF were enrolled to the study. Concentrations of interleukin (IL)-8, epithelial neutrophil activating protein (ENA)-78, interferon-gamma-inducible protein (IP)-10 and interferon-inducible T cell alpha chemoattractant (I-TAC) in BALF supernatants were quantified using Fluorokine MultiAnalyte profiling. RESULTS: There was no significant difference in the BALF chemokine levels between the EAA and IPF group. IL-8 BALF concentrations correlate with the extent of fibrosis in both EAA and IPF (p<0.01). The IP-10 BALF concentrations do not correlate either with the HRCT alveolar or interstitial score and should be evaluated in the relationship with the disease course. CONCLUSIONS: Both IL-8 and ENA-78 probably play a different role in IPF and chronic EAA pathogenesis. While we suggest ENA-78 as the marker of at least partial reversibility of the lung impairment in the EAA patients, IL-8 could be rather an indicator of continuous exposition to provoking agent in EAA patients. IL-8 might serve as a potential marker of early phase of IPF.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a hypersenzitivní pneumonitida $x imunologie $x patologie $7 D000542
650    _2
$a biologické markery $7 D015415
650    _2
$a bronchoalveolární lavážní tekutina $x imunologie $7 D001992
650    _2
$a chemokin CXCL10 $x analýza $7 D054357
650    _2
$a chemokin CXCL11 $x analýza $7 D054371
650    _2
$a chemokin CXCL5 $x analýza $7 D054365
650    _2
$a chemokiny $x analýza $7 D018925
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a idiopatická plicní fibróza $x imunologie $x patologie $7 D054990
650    _2
$a interleukin-8 $x analýza $7 D016209
650    _2
$a plíce $x imunologie $x patologie $7 D008168
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a receptory chemokinů $x analýza $7 D019707
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Martina, Vasakova
700    1_
$a Monika, Metlicka
700    1_
$a Jan, Pavlicek
700    1_
$a Libor, Kolesar
700    1_
$a Ilja, Striz
773    0_
$w MED00004105 $t Respiratory medicine $x 1532-3064 $g Roč. 103, č. 11 (20090616), s. 1651-1656
856    41
$u https://pubmed.ncbi.nlm.nih.gov/19535235 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20140318134406 $b ABA008
999    __
$a ok $b bmc $g 948084 $s 783388
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2009 $b 103 $c 11 $d 1651-1656 $e 20090616 $i 1532-3064 $m Respiratory medicine $n Respir Med $x MED00004105
GRA    __
$a NR9131 $p MZ0
LZP    __
$a Pubmed-20120817/10/03

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...